Copyright
©The Author(s) 2025.
World J Transplant. Jun 18, 2025; 15(2): 100460
Published online Jun 18, 2025. doi: 10.5500/wjt.v15.i2.100460
Published online Jun 18, 2025. doi: 10.5500/wjt.v15.i2.100460
Table 3 Overview of mechanical circulatory support devices, indications, complications, and contraindications
Category | Device | Description | Indications | Complications | Contraindications |
Left ventricular support | IABP | Uses counter pulsations of a balloon in the descending aorta to improve coronary perfusion and cardiac output | AMI with cardiogenic shock, high-risk PCI | Vascular complications (stroke, limb ischemia), thrombocytopenia, infection | Severe aortic regurgitation, aortic aneurysm, aortic dissection, peripheral vascular disease |
Impella (2.5, CP, 5.5) | Nonpulsatile micro axial flow pumps providing up to 5 L/minute support. Available in various models for different levels of LV support | Cardiogenic shock, high-risk PCI | Bleeding, vascular injury, infection, hemolysis, pump migration | Severe peripheral vascular disease, severe aortic stenosis, LV thrombus, mechanical aortic valves | |
HeartMate percutaneous heart pump | Microaxial three-blade impeller pump providing flows up to 5 L/minute | High-risk PCI | Device malfunction, bleeding, thromboembolism | Severe peripheral vascular disease, LV thrombus, mechanical aortic valves | |
Right ventricular support | Impella RP | Minimally invasive microaxial flow pump providing up to 4 L/minute support for RV | Right ventricular failure, postcardiac surgery | Similar to other Impella devices | Tricuspid regurgitation, pulmonary regurgitation |
TandemHeart | Centrifugal continuous flow pump providing 3.5-5 L/minute support, placed via femoral artery and left atrium | Acute RV failure, especially in postcardiac surgery | Bleeding, thromboembolism, limb ischemia | Aortic regurgitation, peripheral vascular disease | |
Protek Duo | Dual-lumen cannula with centrifugal pump for RV support | RV failure, often after LVAD implantation | Similar to other centrifugal devices | Similar to other centrifugal devices | |
CentriMag and Rotaflow | Magnetically levitated centrifugal flow pumps providing up to 10 L/minute | Short-term support in severe cases, including postcardiotomy | Bleeding, infection, device failure | Specific contraindications not detailed | |
Short-term MCS in structural heart valve interventions | IABP | Used to support patients undergoing valve interventions, but may worsen aortic regurgitation | Structural heart disease, transcatheter valve implantation | Worsening aortic regurgitation | |
Impella | Used for aortic stenosis with LV dysfunction, but may worsen stenosis | Aortic stenosis, LV dysfunction | Narrowing of valve orifice, embolic events | Severe aortic stenosis | |
TandemHeart | Limited due to transseptal puncture requirements and increased support time | Aortic stenosis, high-risk interventions | Complications of transseptal puncture | Severe aortic stenosis | |
ECMO | Provides both cardiac and pulmonary support, can be used in various emergent situations | Cardiopulmonary failure, CPR assistance | Harlequin syndrome, bleeding, infection | Multiorgan failure, severe aortic regurgitation | |
Long-term mechanical circulatory support | Durable MCS devices | Includes continuous flow devices (axial and centrifugal) and pulsatile devices | End-stage heart failure | Device-related complications and failure | Patient-specific conditions, generally no broad contraindications |
INCOR® | Berlin Heart. First implant 2002, CE mark 2003 | End-stage heart failure | Device-related complications and failure | Patient-specific conditions | |
HVAD® | Medtronic. CE mark 2008, FDA approval BTT 2012, FDA approval lateral implantation 2015 | End-stage heart failure | Device-related complications and failure | Patient-specific conditions | |
HeartMate II® | Abbott Laboratories. First implant 2003, FDA approval BTT 2008, DT 2010 | End-stage heart failure | Device-related complications and failure | Patient-specific conditions | |
HeartMate 3® | Abbott Laboratories. First implant 2014, CE mark 2015 | End-stage heart failure | Device-related complications and failure | Patient-specific conditions | |
EVAHEART 2® | Evaheart Inc. First implants 2005 in Japan, IDE approval by FDA, BTT trial ongoing | End-stage heart failure | Device-related complications and failure | Patient-specific conditions | |
Jarvik 2000® | Jarvik Heart. First implant 2000, CE mark 2005, FDA approval BTT 2005, DT trial ongoing | End-stage heart failure | Device-related complications and failure | Patient-specific conditions | |
Heart Assist 5® | Reliant Heart Inc. First implant 1998, CE mark 2001, BTT trial ongoing | End-stage heart failure | Device-related complications and failure | Patient-specific conditions | |
EXCOR® | Berlin Heart. First implant 1990, CE mark 1996 | End-stage heart failure | Device-related complications and failure | Patient-specific conditions | |
SynCardia total artificial hearts® | SynCardia. First implant 1986, FDA approval BTT 2004 | End-stage heart failure | Device-related complications and failure | Patient-specific conditions | |
Carmat total artificial hearts® | Carmat SA. First implant 2013, investigational device | End-stage heart failure | Device-related complications and failure | Patient-specific conditions |
- Citation: Sundararaju U, Rachoori S, Mohammad A, Rajakumar HK. Cardiac transplantation: A review of current status and emerging innovations. World J Transplant 2025; 15(2): 100460
- URL: https://www.wjgnet.com/2220-3230/full/v15/i2/100460.htm
- DOI: https://dx.doi.org/10.5500/wjt.v15.i2.100460